近年来，苏州每年新增肿瘤患者约5万人，且呈年轻化趋势。相较一般慢性病的长期隐性危害，癌 症以其"病程进展快、治疗费用高、家庭冲击大"的特点，成为疾病防治亟待集中力量突破的"攻坚战"。 市委、市政府高度重视肿瘤等重大疾病防治工作。今年5月，我市启动了融通"三医"数据的"新三大中 心"建设，邀请国内顶尖专家组建苏州市肿瘤防治学术委员会，借助数智赋能，建立全域肿瘤"防筛诊治 康"协同"一张网"，减少肿瘤患者跨地域就医负担。 家住太仓的张女士罹患乳腺癌，现就诊于太仓市中医医院。昨天（11月21日）上午，该院通过乳腺 肿瘤防治一体化协同体系，与牵头医院——苏州大学附属第二医院发起了一场会诊。过程中，苏州大学 附属第一医院、苏州市立医院的乳腺肿瘤专家也参与进来，形成一场跨院且贯通市县全域的多学科会 诊，共同为张女士探讨精准治疗方案。视病情评估需要，苏大附二院甲乳外科主任蒋国勤教授还会带团 队前往基层，在当地为患者提供线下协作诊治。 苏大附二院副院长张力元介绍，该院目前承担了乳腺、甲状腺、结直肠肿瘤防治一体化协同体系的 建设任务。通过该体系，医院将通过"传、帮、带"的形式，推广规范诊疗，强化上下联动，推进学专科 间的横向协 ...

Core Viewpoint - The recent election results for the Chinese Academy of Sciences and the Chinese Academy of Engineering highlight a significant focus on cancer research, particularly in liver and gastrointestinal cancers, with notable advancements in prevention and early diagnosis [3][4]. Group 1: New Academicians - A total of 73 new academicians were elected to the Chinese Academy of Sciences, and 71 to the Chinese Academy of Engineering [3]. - Among the newly elected academicians, significant contributions come from experts in clinical medicine, particularly in cancer research [3]. Group 2: Focus on Liver Cancer - The field of liver cancer remains a critical area of research, with approximately 900,000 new cases globally each year, and China accounting for nearly half of these cases [3]. - A major report published in The Lancet by academicians Zhou Jian and Fan Jia indicates that at least 60% of liver cancer cases are preventable through risk factor reduction [4]. Group 3: Innovations in Diagnosis and Treatment - Zhou Jian and Fan Jia have developed a miRNA-based early diagnosis model for liver cancer, which has been successfully transformed into a clinical application, significantly improving early detection rates compared to traditional markers [5]. - The overall survival rate for treated patients has reached an international leading level due to innovative personalized treatment strategies [5]. Group 4: Gastrointestinal Cancer Research - Gastrointestinal cancer also has a high incidence rate in China, with significant contributions from academician Fang Jingyuan in early diagnosis, prevention, and comprehensive treatment strategies [5].

在新当选中国科学院院士的上海医院专家中，周俭致力于肝胆肿瘤临床和基础研究，曾5次获国家科技 进步奖；房静远专注于胃肠癌的防治。至此，中山医院现有包括葛均波、樊嘉、周俭3位中国科学院院 士；而仁济医院也拥有中国工程院院士夏强和中国科学院院士房静远2名院士。 从此次新增院士名单来看，肿瘤等重大疾病领域依然是院士聚集的高地。以周俭所在的肝癌领域为例， 全球每年新发肝癌病例约90万例，中国占比接近一半。 从此次新增院士名单来看，肿瘤等重大疾病领域依然是院士聚集的高地。 中国科学院、中国工程院11月21日公布2025年院士增选结果，分别选举产生中国科学院院士73人，中国 工程院院士71人。新当选的中国科学院院士中，生命科学和医学学部13人，来自上海的复旦大学附属中 山医院周俭和上海交大附属仁济医院房静远当选。 其他当选中国科学院院士的临床医学专家还包括浙江大学医学院附属邵逸夫医院蔡秀军、首都医科大学 附属北京天坛医院王拥军、中国医学科学院北京协和医院朱兰（女）。 周俭表示："这些成功经验有力证明，肝癌完全可以像高血压、糖尿病一样，被作为可防、可控、可治 的慢性病来管理。" 此外，周俭与樊嘉院士共同创建的miRNA肝癌早 ...

Core Viewpoint - The 2025 CACA Northeast Integrated Oncology Conference was held in Shenyang, focusing on the theme of "Cancer Prevention and Treatment, Winning through Integration" [1] Group 1: Conference Overview - The conference was organized by the China Anti-Cancer Association (CACA) and co-hosted by various institutions, including the World Association of Integrated Oncology (WAIO) [1] - The event aimed to promote the "Chinese solution" for cancer prevention and treatment globally, with over 400 collaborative units established across the country [1] Group 2: Key Messages from Leaders - Fan Daiming, the chairman of the conference and CACA president, emphasized the importance of the CACA guidelines, which are disseminated in 16 languages [1] - Chen Yanlan, from the Liaoning Provincial Health Commission, highlighted the integration of cancer prevention into the overall health strategy of Liaoning Province [1] Group 3: Hospital's Role in Cancer Treatment - Liu Hongxu, the secretary of the Liaoning Provincial Tumor Hospital, stated that traditional treatment models are inadequate for the complexities of cancer, advocating for integrated medical approaches [2] - The hospital aims to enhance early diagnosis, standardized treatment, and comprehensive management of cancer patients [2]

Core Insights - The 28th CSCO Annual Meeting was held in Jinan, Shandong, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Hysco Clinical Oncology Research Foundation, featuring 75 academic sessions and around 1,500 expert speakers, including over 30 international experts from 15 countries [1][2] Group 1: Academic Collaboration - CSCO aims to deepen international cooperation in cancer prevention and treatment, with dialogues planned with high-level representatives from ESMO and other organizations to explore new opportunities [2] - ASCO expressed its commitment to maintaining a strong collaborative relationship with CSCO, emphasizing joint scientific meetings and various initiatives to enhance global oncology development [3] Group 2: Recognition and Awards - CSCO awarded the Annual Achievement Award to three scholars for their significant contributions to clinical oncology, highlighting the importance of innovation and impact in the field [4] - Ten outstanding research papers were recognized, focusing on treatment strategies, new drug development, biomarker exploration, and real-world data analysis, showcasing the depth and innovation of Chinese oncology research [4] Group 3: Academic Content and Innovation - The conference featured 75 academic sessions, emphasizing original research and evidence-based medicine, with a focus on new therapies like ADC and CAR-T/CAR-NK, and addressing major cancer types through AI-focused sessions [6] - The meeting also highlighted the management of cancer as a chronic disease, with a focus on patient quality of life and long-term survival, alongside the release of new clinical guidelines [6] Group 4: Future Directions - The theme of the conference, "Standardized Diagnosis and Treatment, Innovative Leadership," included 530 academic reports and 196 oral presentations, aiming to translate research achievements into clinical practice [7] - The event serves as a key platform for the Chinese oncology community to showcase achievements and foster collaboration, ultimately enhancing cancer prevention and treatment standards in China [7]

Core Viewpoint - The establishment of the Inner Mongolia Tumor Specialty Alliance marks a new development phase in cancer prevention and treatment in Inner Mongolia, aiming to optimize medical resource allocation and enhance grassroots diagnostic capabilities [1][2] Group 1: Alliance Formation and Objectives - The alliance is led by the Inner Mongolia Hospital of Peking University Cancer Hospital, leveraging its resources to improve diagnostic levels through expert dispatch, remote consultations, and standardized training [1] - The initiative aims to provide high-quality cancer treatment services locally, reducing the burden of seeking medical care and enhancing health accessibility for residents [1] Group 2: Mechanisms and Practices - The alliance will establish a long-term mechanism for standardized cancer diagnosis and treatment, early screening, talent cultivation, and research collaboration [1] - A two-way referral system and a tumor disease referral guide will be implemented to facilitate patient transfers between different levels of medical institutions [1] Group 3: Training and Education - The alliance will create a training system for tumor specialists and conduct relevant training programs [2] - Remote medical platforms will be utilized for lectures, case discussions, and academic exchanges to enhance the service capabilities of grassroots medical institutions [2] - Future initiatives include continuing medical education projects, academic seminars, and clinical research on new interventional techniques in oncology [2]

Core Insights - The event marked the recognition of China Resources Pharmaceutical Group as a member of the China Anti-Cancer Association, highlighting the collaboration between the two entities in cancer prevention and treatment [2][4][6] Group 1: Event Overview - The event was themed "Empowerment through Integration" and included a visit to the innovation center of China Resources Pharmaceutical Group, showcasing its patient-centered innovations over 75 years [4][5] - Key figures from the China Anti-Cancer Association, including its president and vice presidents, attended the event, emphasizing the importance of collaboration in cancer treatment [2][6] Group 2: Strategic Initiatives - The China Anti-Cancer Association introduced 17 strategic measures under the guidance of integrated medicine, aiming to enhance cancer prevention and treatment in China [5][6] - The association's "China Cancer Integrated Diagnosis and Treatment Guidelines" established a comprehensive system for cancer care, including over 70 technical guidelines and 60 cancer type guidelines [5][6] Group 3: Industry Collaboration - China Resources Pharmaceutical Group aims to integrate resources across research, education, and application to improve patient access to innovative drugs, positioning itself as a leader in the pharmaceutical distribution sector [6][9] - The company plans to enhance collaboration with the China Anti-Cancer Association to build a new ecosystem for cancer prevention and treatment, supporting the Healthy China strategy [6][9] Group 4: Challenges and Opportunities - The Chinese pharmaceutical industry is entering a new phase driven by product innovation, but faces challenges such as shortened product life cycles and commercialization difficulties [6][9] - The company is leveraging its extensive distribution network and experience to improve patient accessibility and address the challenges in drug availability and payment [6][9]

Group 1: Cancer Prevention and Health Education - The 31st National Cancer Prevention and Control Publicity Week emphasizes the theme "Scientific Cancer Prevention, Healthy Living" [1] - Jiangsu Provincial People's Hospital advocates for a health-centered approach to cancer prevention, focusing on health education and improving public health literacy [1] - The hospital suggests integrating health education into its development plan, establishing dedicated health education departments, and enhancing the scientific literacy of medical staff through training [1] Group 2: Comprehensive Cancer Care - Jiangsu Provincial People's Hospital adopts a multidisciplinary treatment model, establishing specialized centers for lymphoma, gastric tumors, and thyroid cancer to manage patient care throughout the entire process [2] - The hospital has upgraded traditional treatment processes to full-cycle rehabilitation management, incorporating resources from traditional Chinese medicine, nutrition, and rehabilitation [2] - The complexity of lymphoma, with over 100 pathological subtypes, necessitates precise diagnosis and individualized treatment plans, focusing on pre-hospital assessments and post-discharge home management [2] Group 3: Research and Innovation in Cancer Treatment - There is a call for increased research into the mechanisms of lymphoma and drug resistance, as well as the exploration of clinical translation pathways [2] - Advances in basic research have led to the development of innovative therapies such as monoclonal antibodies, bispecific antibodies, and cell therapies, significantly improving clinical outcomes for lymphoma patients [2] - The goal is to translate research and clinical experiences into innovative drugs that effectively serve patients with hematological diseases and lymphomas [2]

Core Viewpoint - The article emphasizes the importance of cancer prevention and control, particularly focusing on gastric cancer, and highlights the upcoming educational initiatives aimed at raising public awareness and improving health outcomes [1]. Group 1: Cancer Prevention and Awareness - The 31st National Cancer Prevention Week will take place from April 15 to 21, 2025, aiming to promote cancer prevention knowledge and encourage individuals to take responsibility for their health [1]. - The "People's Good Doctor · Jinshan Camellia Plan" series will feature experts discussing cancer prevention and treatment, fostering a supportive social atmosphere for cancer control [1]. Group 2: Gastric Cancer Focus - Gastric cancer is identified as a common malignant tumor with high incidence and mortality rates, posing significant challenges to public health and causing substantial suffering for patients and families [1]. - Understanding the causes, symptoms, treatment, and prevention of gastric cancer is crucial for enhancing public health awareness, promoting early detection, and improving patient quality of life [1]. Group 3: Expert Participation - Dr. Chen Xiaobing and Dr. Lu Jun will participate in a live session on April 28, 2025, to address questions related to gastric cancer prevention and treatment [1][2]. - Dr. Chen Xiaobing is a senior physician and a recognized expert in oncology, while Dr. Lu Jun is a vice chief physician with extensive experience in gastric surgery [2]. Group 4: Accessing the Live Session - The live session can be accessed through the People's Good Doctor App, where users can click on the "Famous Doctor Live" section to watch [3]. - Additional health education resources and interactive sessions with top doctors are available through the People's Good Doctor App and the People's Health public WeChat account [4].

Core Viewpoint - The article emphasizes the rising incidence of urinary system tumors in China, particularly prostate, bladder, and kidney cancers, and highlights the importance of early screening, comprehensive treatment, and multidisciplinary collaboration in cancer prevention and control [1][2]. Group 1: Rising Incidence and Risk Factors - The incidence of urinary tumors is positively correlated with economic development and lifestyle changes, especially in coastal eastern regions of China [2] - High-risk groups include elderly males, individuals with a family history, long-term smokers, and those exposed to chemical pollutants [2] - Smoking is closely linked to kidney and bladder cancers, while poor drinking habits and the consumption of carbonated beverages may also contribute to urinary tumors [2] Group 2: Early Detection and Screening Recommendations - Early symptoms of urinary tumors are often subtle and easily overlooked, necessitating regular screenings starting at age 50 for the general population and at 45 for high-risk individuals [3] - Recommended screening methods include PSA testing for prostate cancer, ultrasound, and urinalysis for bladder and kidney cancers, with further diagnostic procedures as needed [3][4] Group 3: Innovations in Treatment - Advances in targeted therapies, immunotherapy, and robotic surgery are providing new hope for patients [5] - Genetic testing can guide precision medicine, such as using PARP inhibitors for prostate cancer patients with BRCA mutations and antibody-drug conjugates for bladder cancer patients with HER2 overexpression [5] - Robotic-assisted surgeries enhance precision in tumor removal while preserving patient quality of life [5] Group 4: Multidisciplinary Collaboration and Standardization - The multidisciplinary treatment (MDT) model is crucial for managing complex cases, requiring collaboration among various medical specialties [6] - The "China Cancer Integrated Diagnosis and Treatment Guidelines" provides a standardized framework for grassroots hospitals [6] - Shandong University Qilu Hospital promotes resource sharing and standardized treatment through academic exchanges and online consultations [6]